Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Femasys Inc. - Common Stock (NQ:FEMY)

1.625 +0.085 (+5.52%)
Streaming Delayed Price Updated: 3:48 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 527,183
Open 1.570
Bid (Size) 1.620 (11)
Ask (Size) 1.630 (1)
Prev. Close 1.540
Today's Range 1.570 - 1.740
52wk Range 0.8600 - 2.120
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option 
From Femasys Inc.
Via GlobeNewswire
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire

Performance

YTD
+47.7%
+47.7%
1 Month
+2.8%
+2.8%
3 Month
+42.5%
+42.5%
6 Month
+49.1%
+49.1%
1 Year
-16.2%
-16.2%

More News

Read More
Assessing Femasys: Insights From 4 Financial Analysts
Via Benzinga
The Latest Analyst Ratings For Femasys
Via Benzinga
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
From Femasys Inc.
Via GlobeNewswire
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
From Femasys Inc.
Via GlobeNewswire
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Femasys to Exhibit at the Annual AAGL 2024 Global Conference
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed
From Femasys Inc.
Via GlobeNewswire
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
From Femasys Inc.
Via GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From Femasys Inc.
Via GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
From Femasys Inc.
Via GlobeNewswire
Femasys Announces Infertility Clinic Customers from Coast to Coast
From Femasys Inc.
Via GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
From Femasys Inc.
Via GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
From Femasys Inc.
Via GlobeNewswire
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Frequently Asked Questions

Is Femasys Inc. - Common Stock publicly traded?
Yes, Femasys Inc. - Common Stock is publicly traded.
What exchange does Femasys Inc. - Common Stock trade on?
Femasys Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Femasys Inc. - Common Stock?
The ticker symbol for Femasys Inc. - Common Stock is FEMY on the Nasdaq Stock Market
What is the current price of Femasys Inc. - Common Stock?
The current price of Femasys Inc. - Common Stock is 1.625
When was Femasys Inc. - Common Stock last traded?
The last trade of Femasys Inc. - Common Stock was at 03/19/25 03:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.